UNRESECTABLE HEAD AND NECK SQUAMOUS CELL CARCINOMA
Clinical trials for UNRESECTABLE HEAD AND NECK SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE HEAD AND NECK SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE HEAD AND NECK SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug duo aims to shrink tough head and neck cancers
Disease control OngoingThis study is testing whether a combination of two drugs, pembrolizumab and cabozantinib, can help control advanced head and neck cancer that has come back or spread. The trial will involve about 36 patients whose cancer cannot be removed by surgery. Researchers want to see if th…
Matched conditions: UNRESECTABLE HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
New Immune-Boosting combo tested in fight against tough head and neck cancers
Disease control OngoingThis study is testing a combination of two drugs, cetuximab and interleukin-12 (IL-12), for people with advanced head and neck cancer that has returned, spread, or cannot be surgically removed. The first goal is to find a safe dose of IL-12 to use with cetuximab. The second goal …
Matched conditions: UNRESECTABLE HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
New cancer vaccine combo aims to outperform standard treatment in major trial
Disease control OngoingThis large, late-stage trial is testing whether adding an experimental immunotherapy called PDS0101 to the standard drug pembrolizumab (Keytruda) helps people with advanced HPV-positive head and neck cancer live longer. The study will enroll about 351 adults whose cancer has retu…
Matched conditions: UNRESECTABLE HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: PDS Biotechnology Corp. • Aim: Disease control
Last updated Mar 10, 2026 12:53 UTC